Founded in 1942, Lannett is headquartered in Philadelphia, Pennsylvania, and began trading on the American Stock Exchange in 2002. The company manufactures and distributes generics, and historically has sold them under trade or brand names.Lannett tries to avoid going down the route of developing off-patent blockbuster drugs, but looks instead to developing other generic drugs with more secure markets and less competition. Additionally, the company pursues long-term alliances with API suppliers. Lannett also licenses the marketing of its products to other manufacturers.Lannett reported net sales worth US$119.0 million in fiscal 2009, up from US$72.4 million a year earlier. The firm cited increased sales of drugs to treat thyroid deficiency and heart failure, along with the introduction of prenatal vitamins. The firm reported that sales had risen by 164% between fiscal year 2005 and fiscal year 2009.The firm reported in June 2009 that over the previous five years it had experienced a 164% growth in its revenues from around US$45 million in fiscal year 2005 to over US$119 million in fiscal year 2009. Lannett commented that the rapid growth had been achieved through strategic partnerships and opportunities resulting from certain difficulties its competitors had experienced with regulatory compliance.In 2004, the firm entered into an exclusive distribution agreement with Jerome Stevens Pharmaceuticals covering four product lines. Two of these accounted for around 62% of net sales in fiscal year 2009. In 2008, Lannett completed its acquisition of Cody Laboratories, which became one of seven companies in the US to be granted a licence from the DEA to directly import raw poppy straw.This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Lannett Generics Company Intelligence Report
Published on April 2010
Report Summary
Founded in 1942, Lannett is headquartered in Philadelphia, Pennsylvania, and began trading on the American Stock Exchange in
2002. The company manufactures and distributes generics, and historically has sold them under trade or brand names.
Lannett tries to avoid going down the route of developing off-patent blockbuster drugs, but looks instead to developing other generic
drugs with more secure markets and less competition. Additionally, the company pursues long-term alliances with API suppliers.
Lannett also licenses the marketing of its products to other manufacturers.
Lannett reported net sales worth US$119.0 million in fiscal 2009, up from US$72.4 million a year earlier. The firm cited increased
sales of drugs to treat thyroid deficiency and heart failure, along with the introduction of prenatal vitamins. The firm reported that sales
had risen by 164% between fiscal year 2005 and fiscal year 2009.
The firm reported in June 2009 that over the previous five years it had experienced a 164% growth in its revenues from around
US$45 million in fiscal year 2005 to over US$119 million in fiscal year 2009. Lannett commented that the rapid growth had been
achieved through strategic partnerships and opportunities resulting from certain difficulties its competitors had experienced with
regulatory compliance.
In 2004, the firm entered into an exclusive distribution agreement with Jerome Stevens Pharmaceuticals covering four product lines.
Two of these accounted for around 62% of net sales in fiscal year 2009. In 2008, Lannett completed its acquisition of Cody
Laboratories, which became one of seven companies in the US to be granted a licence from the DEA to directly import raw poppy
straw.
This report provides information on the company's active product lines and ANDA approvals, along with a review of major
developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial
results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's
progress.
Table of Content
Contents
Executive Summary..........1
Introduction ..........2
Products .3
Lupin ANDA Approvals, January 2002 ' December 2009 ............ 4
Recent Product Approvals...... 4
Amlodipine / benazepril (US) ... 4
Lannett Generics Company Intelligence Report Page 1/4

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Perindopril (US)........... 5
Memantine (US, tentative) ....... 5
Levetiracetam (US) ..... 5
Financial results...6
Latest Quarterly Results, 3Q09-10 ....... 6
Lupin: Consolidated Quarterly Results, in Rs millions...... 6
Lupin: Consolidated Quarterly Results, in US$ millions ... 6
Latest Yearly Results. 7
Lupin: Consolidated Fiscal Year Results, in Rs millions .. 7
Lupin: Consolidated Fiscal Year Results, in US$ millions 7
Segment breakdown ... 7
United States.... 7
Europe . 8
India..... 8
Major developments .........8
Lupin's Mandideep facility gains FDA approval .. 8
Mergers, acquisitions and agreements8
Salix acquires US rights to Lupin's bioadhesive technology for rifaximin product .. 8
Lupin acquires US rights to branded fenofibrate capsules ........... 9
Lupin gains worldwide rights for triamcinolone NDA........ 9
Lupin and Natco form alliance to commercialise lanthanum...... 10
Lupin acquires majority stake in Multicare Pharmaceuticals Philippines. 10
Lupin enters equity partnership with South Africa's Pharma Dynamics .. 10
Litigation...... 11
Depomed files lawsuit against Lupin... 11
Warner Chilcott files oral contraceptive litigation against Lupin.. 11
Lupin settles venlafaxine litigation with Wyeth.. 12
Oscient and Ethypharm launch fenofibrate lawsuit against Lupin ........... 12
Lupin enters desloratadine litigation settlement 13
Contact Details...14
Lannett Generics Company Intelligence Report Page 2/4

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Lannett Generics Company Intelligence Report
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 306.25 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Lannett Generics Company Intelligence Report Page 3/4

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Lannett Generics Company Intelligence Report Page 4/4